---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005094"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:19:17.131722+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Phio shareholders approve incentive plan amendment, adding 125,500 shares

## Summary
- At July 20, 2023 annual meeting, shareholders approved amendment to 2020 Long Term Incentive Plan.
- Plan shares increased by 125,500 to a total of 225,500 shares available for issuance.
- All five director nominees elected: Bitterman, Bradford, Ferrara, Freeman, Lockshin.
- BDO USA LLP ratified as independent auditor for FY 2023 with 605,026 for, 21,903 against.

## SEC filing metadata
- accession: 0001683168-23-005094
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005094
- JSON: https://secwatch.observer/filing/0001683168-23-005094.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005094.txt

## Key facts
- Shareholder Votes
  Phio Pharmaceuticals Corp. shareholders approved Ratification of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-07-20 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-07-20
  source text: Proposal 2: Ratification of Auditors For Against Abstain 605,026 21,903 3,171
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm
- Shareholder Votes
  Phio Pharmaceuticals Corp. shareholders approved Election of five directors to serve until the 2024 Annual Meeting at the 2023-07-20 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-07-20
  source text: Nominee For Withheld Broker Non-Votes Robert J. Bitterman 126,094 17,995 486,011
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm
- Shareholder Votes
  Phio Pharmaceuticals Corp. shareholders approved Amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares by 125,500 at the 2023-07-20 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-07-20
  source text: Proposal 3: Amendment and Restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan For Against Abstain Broker Non-Votes 98,254 44,696 1,139 486,011
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.